#1 Clinical Trials Search in Europe

Pivmecillinam Hydrochloride

Pivmecillinam Hydrochloride, an antibiotic medication, is being studied in several clinical trials for its effectiveness in treating various urinary tract infections (UTIs) and other conditions. These trials aim to evaluate its efficacy, safety, and potential as an alternative to other antibiotics, especially in cases of antibiotic-resistant infections. The research spans from uncomplicated UTIs to more complex scenarios like post-surgical infections and bacteremia.

Table of Contents

What is Pivmecillinam Hydrochloride?

Pivmecillinam hydrochloride is an antibiotic medication used to treat various types of bacterial infections, particularly those affecting the urinary tract. It belongs to the class of antibiotics known as penicillins. Pivmecillinam is also known by other names such as Selexid, Penomax, or Coactin, depending on the brand and country where it’s marketed[1][2].

What Conditions Does Pivmecillinam Treat?

Pivmecillinam is primarily used to treat the following conditions:

  • Uncomplicated Urinary Tract Infections (UTIs): These are infections that affect the bladder and urethra, causing symptoms like frequent urination, burning sensation while urinating, and lower abdominal pain[2].
  • Pyelonephritis: This is a more serious type of UTI that affects the kidneys, often causing fever and back pain along with typical UTI symptoms[1].
  • Urosepsis: A severe complication of UTIs where the infection spreads to the bloodstream, potentially causing a life-threatening condition[1].

How Does Pivmecillinam Work?

Pivmecillinam works by targeting and killing the bacteria that cause urinary tract infections. It is particularly effective against a type of bacteria called Escherichia coli (E. coli), which is responsible for most UTIs. The medication interferes with the bacteria’s ability to build their cell walls, ultimately leading to their destruction[1].

How is Pivmecillinam Administered?

Pivmecillinam is typically taken orally in tablet form. The dosage and duration of treatment can vary depending on the specific condition being treated and the severity of the infection. Some common dosage regimens observed in clinical trials include:

  • 400 mg taken three times daily for 3-5 days for uncomplicated UTIs[2][5].
  • 400 mg taken four times daily for more severe infections like pyelonephritis or urosepsis[1].

It’s important to note that the exact dosage should always be determined by a healthcare professional based on individual patient factors.

Effectiveness of Pivmecillinam

Pivmecillinam has shown high effectiveness against E. coli, the most common cause of UTIs. It is considered a valuable antibiotic option due to its targeted action and the relatively low rates of bacterial resistance to it. Clinical trials are ongoing to further evaluate its effectiveness compared to other antibiotics, especially in cases where bacteria have developed resistance to commonly used antibiotics[1][2].

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to investigate various aspects of pivmecillinam use:

  • A study comparing pivmecillinam to other antibiotics like fosfomycin and nitrofurantoin for treating uncomplicated UTIs in women[5].
  • Research on the effectiveness of pivmecillinam in treating pyelonephritis and urosepsis caused by E. coli[1].
  • A trial investigating the combination of pivmecillinam with amoxicillin/clavulanic acid for treating UTIs caused by antibiotic-resistant bacteria[6].

These ongoing studies aim to provide more evidence on the optimal use of pivmecillinam in various clinical scenarios.

Potential Side Effects

Like all medications, pivmecillinam can cause side effects in some patients. Common side effects may include:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Skin rash

More serious side effects are rare but can occur. It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking the medication[1].

Aspect Details
Main Conditions Studied Urinary Tract Infections (UTIs), Pyelonephritis, Urosepsis, Antibiotic-Resistant Infections
Comparator Drugs Ciprofloxacin, Fosfomycin, Nitrofurantoin, Trimethoprim/Sulfamethoxazole, Ertapenem
Key Outcome Measures Clinical effectiveness, Bacteriological eradication, Infection-related readmission rates, Adverse events
Treatment Durations Single dose to 5 days for uncomplicated UTIs; Longer for complex infections
Special Populations Post-cystectomy patients, Patients with antibiotic-resistant infections
Innovative Approaches Combination therapy (e.g., Pivmecillinam with amoxicillin/clavulanic acid), Targeted antibiotic prophylaxis

FAQ

  • What is Pivmecillinam Hydrochloride used for in these clinical trials? Pivmecillinam Hydrochloride is primarily being studied for treating various types of urinary tract infections (UTIs), including uncomplicated UTIs, pyelonephritis, and urosepsis. It's also being investigated as a potential treatment for infections caused by antibiotic-resistant bacteria.
  • How does Pivmecillinam Hydrochloride compare to other antibiotics in the trials? The trials are comparing Pivmecillinam Hydrochloride to other antibiotics like ciprofloxacin, fosfomycin, and nitrofurantoin. Some studies are also looking at combination therapies, such as Pivmecillinam with amoxicillin/clavulanic acid, to evaluate their effectiveness against resistant bacteria.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include clinical effectiveness (resolution of symptoms), bacteriological eradication (clearance of bacteria from urine), infection-related readmission rates, and the incidence of adverse events or side effects.
  • How long are the treatment courses in these trials? The treatment courses vary depending on the specific trial and condition being treated. They range from single-dose treatments to courses lasting up to 5 days for uncomplicated UTIs, and longer durations for more complex infections.
  • Are there any special populations being studied in these trials? While most trials focus on adult women with UTIs, some studies are looking at specific populations such as patients undergoing cystectomy (bladder removal surgery) or those with infections caused by antibiotic-resistant bacteria.

Ongoing Clinical Trials on Pivmecillinam Hydrochloride

  • Comparing pivmecillinam and gentamicin with standard treatments for hospitalized adults with complicated urinary tract infections

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of pivmecillinam compared to standard antibiotics for treating Escherichia coli urinary tract infection with fever

    Recruiting

    1 1 1
    Investigated drugs:
    Norway Sweden

  • Study on Reducing Infections After Bladder Removal Surgery Using Pivmecillinam Hydrochloride and Other Antibiotics for Patients Undergoing Ureteral Stent Removal

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of Pivmecillinam and Amoxicillin/Clavulanic Acid for Treating Urinary Tract Infections in Patients with Multidrug-Resistant Bacteria

    Recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • MV140 for Women with Recurrent Uncomplicated Urinary Tract Infections

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Portugal

  • Testing Antibiotic Treatment Strategies for Patients with Bladder Bacteria Without Symptoms Receiving Botulinum Toxin A Bladder Injections

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Pivmecillinam Hydrochloride: An antibiotic medication used to treat various bacterial infections, particularly urinary tract infections.
  • Urinary Tract Infection (UTI): An infection affecting any part of the urinary system, including the kidneys, bladder, ureters, and urethra.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.
  • Urosepsis: A severe infection that starts in the urinary tract and spreads to the bloodstream, potentially causing a life-threatening condition.
  • Extended Spectrum Beta-Lactamase (ESBL): Enzymes produced by some bacteria that can break down certain antibiotics, making the bacteria resistant to these drugs.
  • Bacteremia: The presence of bacteria in the bloodstream.
  • Colony Forming Units (CFU): A measure used to estimate the number of viable bacteria or fungal cells in a sample.
  • Antibiotic Resistance: The ability of bacteria to survive exposure to antibiotics that would normally kill them or stop their growth.
  • Cystectomy: A surgical procedure to remove all or part of the urinary bladder.
  • Empiric Prophylaxis: The use of antibiotics to prevent infection before knowing if an infection is present or what type of bacteria is causing it.

References

  1. https://clinicaltrials.gov/study/NCT03282006
  2. https://clinicaltrials.gov/study/NCT05545137
  3. https://clinicaltrials.gov/study/NCT06709196
  4. https://clinicaltrials.gov/study/NCT03228108
  5. https://clinicaltrials.gov/study/NCT04959331
  6. https://clinicaltrials.eu/trial/study-of-pivmecillinam-and-amoxicillin-clavulanic-acid-for-treating-urinary-tract-infections-in-patients-with-multidrug-resistant-bacteria/